Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...

ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01 ImCheck Achieves Initial Positive Independent Safety Reviewand Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01                        Company Receives FDA Approval for US IND ...

Cotinga Pharmaceuticals Provides Update on COTI-2 Clinical Programs LONDON, Ontario and BOSTON, March 20, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company...

EnLyte Monotherapy Reduces Toxic Homocysteine in Patients With MTHFR Polymorphism: Breakthrough Study Shows Significant Reduction In Toxic Amino Acid Linked To Hundreds Of Diseases SUNSET, La., July 29, 2015 (GLOBE NEWSWIRE) -- A new study shows patients with the MTHFR C677T/A1298C enzyme polymorphism significantly benefit from reduced B vitamin therapy, marketed under the...